Scottish HTA Body OKs Novartis’ Aimovig For Migraine And Eisai’s Lenvima For Cancer
Executive Summary
Scotland’s health technology appraisal body has OKd Novartis’s Aimovig for migraines. England’s NICE has postponed a meeting on the drug after a large number of comments were received following the institute’s initial knockback.
You may also be interested in...
Disappointment For Novartis As England’s NICE Says No To Migraine Drug Again
New cost-effectiveness analyses and an improved deal for Aimovig have failed to change the health technology assessment body's mind about routine funding for the migraine prevention drug.
Novartis Bemused As NICE Says No Again To Migraine Drug Aimovig
The Swiss major is evaluating whether or not there is a case to appeal after the cost watchdog said it is “very uncertain" whether the CGRP inhibitor is more clinically effective for migraine than Botox.
Novartis Gets NICE Headache From Aimovig Knockback
The cost-effectiveness watchdog is worried about the cost of Novartis's once-monthly first-in-class migraine drug and is not convinced it is more effective than Allergan’s Botox, which can require up to 40 injections into the head and neck.